Barclays lowered the firm’s price target on Genmab to DKK 2,800 from DKK 3,000 and keeps an Overweight rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GMAB:
- TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
- Pfizer and Genmab’s sBLA for Tivdak accepted by the FDA
- Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
- Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Genmab to host virtual investor meeting